See more : Charter Communications Inc (CQD.DE) Income Statement Analysis – Financial Results
Complete financial analysis of aTyr Pharma, Inc. (ATYR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of aTyr Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Smartgroup Corporation Ltd (STGXF) Income Statement Analysis – Financial Results
- United Homes Group, Inc. (UHG) Income Statement Analysis – Financial Results
- Vohringer Home Technology Co.,Ltd. (603226.SS) Income Statement Analysis – Financial Results
- International Entertainment Corporation (1009.HK) Income Statement Analysis – Financial Results
- Ecosciences, Inc. (ECEZ) Income Statement Analysis – Financial Results
aTyr Pharma, Inc. (ATYR)
Industry: Biotechnology
Sector: Healthcare
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 353.00K | 10.39M | 0.00 | 10.46M | 422.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.74M | 1.70M | 1.30M | 17.29M | 14.05M | 746.00K | 713.00K | 900.00K | 0.00 | 0.00 | 0.00 | 540.00K |
| Gross Profit | -2.39M | 8.69M | -1.30M | -6.84M | -13.63M | -746.00K | -713.00K | -900.00K | 0.00 | 0.00 | 0.00 | -540.00K |
| Gross Profit Ratio | -676.49% | 83.68% | 0.00% | -65.38% | -3,228.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 42.29M | 42.81M | 23.26M | 17.29M | 14.05M | 20.39M | 30.07M | 44.25M | 34.50M | 16.78M | 13.83M | 7.75M |
| General & Administrative | 12.98M | 13.98M | 10.75M | 9.08M | 9.35M | 0.00 | 0.00 | 0.00 | 13.11M | 6.78M | 5.71M | 0.00 |
| Selling & Marketing | 0.00 | -1.70M | -1.30M | -1.27M | -1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.98M | 12.29M | 9.45M | 7.81M | 7.99M | 11.69M | 16.36M | 14.19M | 13.11M | 6.78M | 5.71M | 4.31M |
| Other Expenses | 0.00 | 1.06M | 238.00K | -319.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 55.27M | 55.10M | 32.71M | 25.10M | 22.03M | 32.07M | 46.43M | 58.44M | 47.62M | 23.55M | 19.54M | 12.06M |
| Cost & Expenses | 55.27M | 56.79M | 34.02M | 26.37M | 23.40M | 32.82M | 47.15M | 59.34M | 47.62M | 23.55M | 19.54M | 12.60M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 65.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 832.00K | 444.00K | 272.00K |
| Depreciation & Amortization | 2.74M | 1.70M | 1.30M | 1.27M | 1.37M | 746.00K | 713.00K | 900.00K | 869.00K | 829.00K | 714.00K | 540.00K |
| EBITDA | -52.18M | -44.71M | -32.47M | -14.65M | -21.61M | -32.07M | -46.43M | -57.00M | -45.35M | -22.73M | -18.83M | -12.05M |
| EBITDA Ratio | -14,781.30% | -430.47% | 0.00% | -140.08% | -5,121.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -54.92M | -46.40M | -34.02M | -15.91M | -22.98M | -32.82M | -47.15M | -59.34M | -47.62M | -23.55M | -19.54M | -12.60M |
| Operating Income Ratio | -15,557.79% | -446.79% | 0.00% | -152.19% | -5,445.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.52M | 1.06M | 238.00K | -319.00K | -785.00K | -1.70M | -1.06M | 1.44M | -357.00K | -796.00K | -472.00K | -261.00K |
| Income Before Tax | -50.40M | -45.34M | -33.78M | -16.23M | -23.76M | -34.52M | -48.21M | -57.90M | -47.97M | -24.35M | -20.01M | -12.86M |
| Income Before Tax Ratio | -14,276.77% | -436.58% | 0.00% | -155.24% | -5,631.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.00K | -9.00K | -6.00K | -160.00K | 1.00 | 0.00 | -49.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -50.39M | -45.34M | -33.77M | -16.22M | -23.60M | -34.52M | -48.21M | -57.86M | -47.97M | -24.35M | -20.01M | -17.61M |
| Net Income Ratio | -14,274.50% | -436.53% | 0.00% | -155.18% | -5,593.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 | -16.13 | -26.16 | -34.20 | -42.42 | -422.73 | -429.90 | -44.67 |
| EPS Diluted | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 | -16.13 | -26.16 | -34.20 | -42.42 | -415.63 | -397.39 | -44.67 |
| Weighted Avg Shares Out | 53.61M | 28.42M | 19.08M | 9.16M | 3.36M | 2.14M | 1.84M | 1.69M | 1.13M | 58.59K | 50.36K | 394.19K |
| Weighted Avg Shares Out (Dil) | 53.61M | 28.42M | 19.08M | 9.16M | 3.36M | 2.14M | 1.84M | 1.69M | 1.13M | 59.59K | 54.48K | 394.19K |
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that...
aTyr Pharma: The Bull Has Finally Come Out
aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without immune suppression, setting it apart from traditional treatments, with promising post-hoc results...
aTyr Pharma to Present at the LD Micro Main Event XVII in October
San Diego, California--(Newsfile Corp. - October 14, 2024) - aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla,...
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to reach a value of $53.3 billion by 2034. Topline data...
aTyr Pharma to Participate in September Investor Conferences
SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate...
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted...
Source: https://incomestatements.info
Category: Stock Reports